Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL Therapy for Patients With Advanced Cancer
NCT06416085Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in cancer, sponsored by University Health Network. Primary endpoints: Recruitment feasibility at 24 months, Retention feasibility at 24 months and 3 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06416085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416085.